Trial reportEuropean heart journal2017
Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.
Trial report in European heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01796912 (Clinical Outcomes, Perfusion and Vascular Function in Patients With Refractory Angina and Raised Lipoprotein), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Outcomes, Perfusion and Vascular Function in Patients With Refractory Angina and Raised Lipoprotein (a), Treated With Lipoprotein Apheresis
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Pooled it
- Society for cardiovascular magnetic resonance expert consensus statement on quantitative myocardial perfusion cardiovascular magnetic resonance imaging.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic ResonanceGuideline
- Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up.European heart journal · 2017Trial
- An injectable hydrogen-producing bacteria hydrogel for cardiac repair in rodent and porcine models.Nature biomedical engineering · 2026Article
- Guideline for Chronic Coronary Syndrome - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Refractory angina: mechanisms and stratified treatment in obstructive and non-obstructive chronic myocardial ischaemic syndromes.European heart journal · 2025Review
- Lipoprotein(a) and High-Risk Coronary Plaques: Mechanisms, Characteristics, and Emerging Therapeutic Strategies.Reviews in cardiovascular medicine · 2025Review
- Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening.American journal of preventive cardiology · 2025Review
- The impact of lipoprotein(a) level on cardiac pathologies in diabetes: a cardiac CT study.European radiology · 2025Article
- Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.International journal of molecular sciences · 2024Article
- Lipoprotein(a) and the atherosclerotic burden - Should we wait for clinical trial evidence before taking action?Atherosclerosis plus · 2024Review
- Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond.American journal of preventive cardiology · 2024Article
- Lipoprotein(a) in Children and Adolescents: Risk or Causal Factor for Cardiovascular Disease? A Narrative Review.International journal of molecular sciences · 2024Review
- The implications of measuring lipoprotein(a) in clinical practice.Global cardiology science & practice · 2024Article
- Oxidized phospholipids in cardiovascular disease.Nature reviews. Cardiology · 2024Review
- Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.Current cardiology reports · 2023Review
- Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a).Current atherosclerosis reports · 2023Review
- Supporting evidence for lipoprotein(a) measurements in clinical practice.Best practice & research. Clinical endocrinology & metabolism · 2023Review
- [State of the art: lipoprotein apheresis].Deutsche medizinische Wochenschrift (1946) · 2023Review
- Apheresis: What Should a Clinician Know?Current atherosclerosis reports · 2023Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
aimsTo determine the clinical impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a) > 500 mg/L on the primary end point of quantitative myocardial perfusion, as well as secondary end points including atheroma burden, exercise capacity, symptoms, and quality of life.
methodsWe conducted a single-blinded randomized controlled trial in 20 patients with refractory angina and raised lipoprotein(a) > 500 mg/L, with 3 months of blinded weekly lipoprotein apheresis or sham, followed by crossover. The primary endpoint was change in quantitative myocardial perfusion reserve (MPR) assessed by cardiovascular magnetic resonance. Secondary endpoints included measures of atheroma burden, exercise capacity, symptoms and quality of life.
resultsThe primary endpoint, namely MPR, increased following apheresis (0.47; 95% CI 0.31-0.63) compared with sham (-0.16; 95% CI - 0.33-0.02) yielding a net treatment increase of 0.63 (95% CI 0.37-0.89; P < 0.001 between groups). Improvements with apheresis compared with sham also occurred in atherosclerotic burden as assessed by total carotid wall volume (P < 0.001), exercise capacity by the 6 min walk test (P = 0.001), 4 of 5 domains of the Seattle angina questionnaire (all P < 0.02) and quality of life physical component summary by the short form 36 survey (P = 0.001).
conclusionLipoprotein apheresis may represent an effective novel treatment for patients with refractory angina and raised lipoprotein(a) improving myocardial perfusion, atheroma burden, exercise capacity and symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.